Sv Health Investors, LLC
Emerging managerSEC-registered investment adviser.
- HQ
- MA
SV Health Investors is a specialist healthcare fund manager that invests across multiple stages and sectors through strategy-specific funds. Its portfolio includes companies such as Quell Therapeutics, Cerevance, OMass Therapeutics, Perfuze, TRexBio, HPS/PayMedix, EpiVax, Draig Therapeutics and Pivot Point Consulting. The firm has also announced the final closing of its second Dementia Discovery Fund, DDF-2.
01 · Says / Does
| Tag | Says | Does | Historically (to 2020) |
|---|---|---|---|
| Stages | Growth | Not enough dated deals | Series A, Series B, Growth |
| Sectors | Healthtech, Digital health | Not enough dated deals | Healthtech, Biotech, Medical devices |
| Regions | Not stated | Not enough dated deals | CA, MA |
Says: what the firm's funds state. Does: from 4 dated deals in the last 24 months.
Historical focus (through 2020), derived from historical deal data.
| Year | Deals | Top sectors |
|---|---|---|
| 2000 | 1 | Biotech, Enterprise SaaS, Hardware |
| 2002 | 3 | Healthtech, Biotech, Medical devices |
| 2004 | 3 | Healthtech, Biotech, Medical devices |
| 2005 | 7 | Healthtech, Biotech, Manufacturing |
| 2006 | 8 | Healthtech, Medical devices, Biotech |
| 2007 | 15 | Healthtech, Biotech, Medical devices |
| 2008 | 12 | Healthtech, Biotech, Medical devices |
| 2009 | 20 | Healthtech, Biotech, Medical devices |
| 2010 | 15 | Biotech, Healthtech, Medical devices |
| 2011 | 22 | Biotech, Healthtech, Medical devices |
| 2012 | 13 | Biotech, Healthtech, Medical devices |
| 2013 | 13 | Healthtech, Biotech, Medical devices |
| 2014 | 8 | Medical devices, Biotech, Healthtech |
| 2015 | 7 | Healthtech, Biotech, Medical devices |
| 2016 | 43 | Healthtech, Biotech, Medical devices |
| 2017 | 8 | Biotech, Healthtech, Life sciences and research tools |
| 2018 | 11 | Biotech, Healthtech, Medical devices |
| 2019 | 6 | Healthtech, Medical devices, Biotech |
| 2020 | 2 | Healthtech, Biotech, Data analytics |
Stage mix over time
- Pre-seed
- Seed
- Series A
- Series B
- Growth
| Year | Pre-seed | Seed | Series A | Series B | Growth |
|---|---|---|---|---|---|
| 2010 | 0 | 2 | 6 | 3 | 4 |
| 2011 | 0 | 0 | 7 | 4 | 7 |
| 2012 | 0 | 0 | 2 | 3 | 3 |
| 2013 | 0 | 1 | 3 | 3 | 3 |
| 2014 | 0 | 0 | 1 | 1 | 2 |
| 2015 | 0 | 0 | 3 | 1 | 2 |
| 2016 | 0 | 1 | 14 | 6 | 5 |
| 2017 | 0 | 1 | 3 | 3 | 1 |
| 2018 | 0 | 0 | 3 | 3 | 4 |
| 2019 | 0 | 0 | 3 | 2 | 0 |
| 2020 | 0 | 0 | 0 | 1 | 1 |
| 2021 | 0 | 0 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 1 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 0 | 0 | 0 | 0 | 0 |
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| SV7 Plus Growth Fund, L.P. The fund provides growth capital and liquidity to growth-stage healthcare companies, accelerating healthcare services, medical products and digital health businesses. Inferred from the firm's website | approx. 2024 | $60M (Form D) | Raising |
03 · People across funds
- Gregory Madden, Managing Member of the General Partner
SV7 Plus Growth Fund, L.P. (Named on Form D)
- Michael Balmuth, Managing Member of the General Partner
SV7 Plus Growth Fund, L.P. (Named on Form D)
- Thomas Flynn, Managing Member of the General Partner
SV7 Plus Growth Fund, L.P. (Named on Form D)
04 · Recent deals
05 · Latest from the firm
- InvestmentSV Health Investors Acquires EpiVax - SV Health InvestorsApr 2, 2026
- InvestmentPivot Point Consulting Emerges as a Unified Healthcare IT Powerhouse Following Its Acquisition by Innovative Consulting Group - SV Health InvestorsFeb 17, 2026
- InvestmentHPS/PayMedix Secures $33 Million Investment - SV Health InvestorsJan 13, 2026
- InvestmentDraig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders - SV Health InvestorsJun 18, 2025
- New fundSV Health Investors’ Dementia Discovery Fund Announces $269m Final Close of DDF-2 - SV Health InvestorsMay 20, 2025
06 · Sources
- https://svhealthinvestors.com
- https://svhealthinvestors.com/news
- https://svhealthinvestors.com/news/sv-health-investors-acquires-epivax
- https://svhealthinvestors.com/news/hps-paymedix-secures-33-million-investment
- https://svhealthinvestors.com/news/sv-health-investors-dementia-discovery-fund-announces-269m-final-close-of-ddf-2
- https://svhealthinvestors.com/news/pivot-point-consulting-emerges-as-a-unified-healthcare-it-powerhouse-following-its-acquisition-by-innovative-consulting-group
- https://svhealthinvestors.com/strategy
- https://svhealthinvestors.com/news/draig-therapeutics-launches-with-140-million-107-million-total-investment-to-advance-its-portfolio-of-next-generation-therapies-for-major-neuropsychiatric-disorders
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026